New PhRMA report: More than 170 medicines in development for diabetes offer patients longer, healthier lives

Hannah Mooney   |     November 14, 2016   |   SHARE THIS

Today, there are more than 30 million Americans suffering from type 1 or type 2 diabetes. Roughly 5 percent of patients have type 1 and 90 to 95 percent suffer from type 2, highlighting the complexity of the disease. Because diabetes is the seventh leading cause of death in the United States, the need for innovative treatments and therapies is greater than it ever has been. America’s biopharmaceutical companies are committed to developing new and innovative medicines for patients in need. And today, patients with diabetes can have more hope than ever before with the significant progress offered by rapid advances in science.

A new PhRMA report, “Medicines in Development for Diabetes,” showcases the more than 170 medicines currently in development for diabetes that offer type 1 and type 2 diabetes patients the chance to live longer, healthier lives.

These medicines in development notably include 40 for type 1 diabetes and 95 for type 2 diabetes.


The report also features an interview with PhRMA’s chief medical officer and executive vice president of science and regulatory advocacy Dr. Bill Chin, where he tells the story of diagnosing his son with type 1 diabetes and how his family and his professional career have both informed his perspective on the disease.

Researchers and scientists at America’s biopharmaceutical companies will continue to persevere in their pursuit of developing new treatments for patients living with diabetes. And while this disease presents a threat to the health of America’s patients and our health care system, patients can be sure that these bold advancements in science will keep providing hope for healthier futures and longer lives.

View the full report here.

Hannah Mooney

Hannah Mooney Hannah is a Senior Manager of Public Affairs at PhRMA developing paid media programs and campaigns as well as assisting other PhRMA team members to cultivate a values-driven messaging platform on the value of the industry and the medicines our companies bring to the health care system. In a former life, she worked in grassroots advocacy and voter contact, supporting Members of Congress, their campaigns, and public affairs organizations with their legislative initiatives in addition to having worked in the U.S. Senate in communications. Hannah enjoys being outdoors and exploring all the city has to offer, teaching cycling classes, and finding new restaurants with good food and better patios in the District.

Topics: Research and Development, Value, diabetes, Patients, From Hope to Cures

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates